

## SUPPLEMENTARY MATERIEL

**e-Table 1: Distribution of anticholinergic drug classes by anticholinergic potency**

<i>Anticholinergic drug class</i>	<i>ATC classification level</i>	<i>Number of different ATC levels</i>	<i>ACB-1</i>	<i>ACB-2/3</i>
Antihistamines	R06A	10	7	3
Opioids	N02A	4	4	0
Alimentary tract and metabolism drugs	A	4	4	0
Anxiolytic drugs	N05B	4	3	1
Antidepressant drugs	N06A	9	2	7
Cardiovascular system drugs	C	14	14	0
Antipsychotic drugs	N05A	11	4	7
Other anticholinergic drugs		15	5	10
<b>Total</b>		<b>71</b>	<b>43 (61%)</b>	<b>28 (39%)</b>

ACB, Anticholinergic Cognitive Burden scale; ATC, Anatomical Therapeutic Chemical classification system.

e-Table 2: Relation between cumulative exposure to anticholinergic drugs over a 3-year period and z-scores on cognitive function tests according to age groups (n=34 267)

Cumulative exposure to AC treatment	Episodic memory				Verbal fluency				Executive functions					
	Free recall		Delayed free recall		Semantic fluency		Phonemic fluency		DSST		TMT-A		TMT-B	
	Estimate (Std. Error)		Estimate (Std. Error)		Estimate (Std. Error)		Estimate (Std. Error)		Estimate (Std. Error)		Estimate (Std. Error)		Estimate (Std. Error)	
<b>45 to 64 years (n=27010)</b>														
<b>No delivery</b>	14289	Ref		Ref										
<b>0_3 months</b>	8347	-0.008 (0.006)		-0.015 (0.006)	*	-0.039 (0.006)	***	-0.003 (0.006)		-0.012 (0.006)	*	0.002 (0.006)		-0.008 (0.006)
<b>3_12 months</b>	2680	-0.052 (0.009)	***	-0.048 (0.009)	***	-0.059 (0.010)	***	-0.007 (0.010)		0.000 (0.009)		0.007 (0.010)		-0.015 (0.010)
<b>1_3 years</b>	1282	-0.016 (0.013)		-0.032 (0.013)	*	-0.058 (0.013)	***	0.016 (0.013)		-0.037 (0.013)	**	-0.050 (0.013)	***	-0.014 (0.013)
<b>&gt;3 years</b>	412	-0.139 (0.022)	***	-0.134 (0.022)	***	-0.047 (0.023)	*	-0.059 (0.023)	**	-0.221 (0.022)	***	-0.160 (0.023)	***	-0.183 (0.023) ***
<b>65 years and older (n=7257)</b>														
<b>No delivery</b>	3806	Ref		Ref										
<b>0_3 months</b>	2090	0.006 (0.013)		0.024 (0.013)		0.035 (0.012)	**	0.020 (0.012)		0.001 (0.011)		0.007 (0.010)		0.014 (0.010)
<b>3_12 months</b>	705	-0.048 (0.019)	*	-0.018 (0.020)		0.044 (0.018)	*	0.001 (0.018)		-0.096 (0.017)	***	-0.019 (0.015)		-0.032 (0.016) *
<b>1_3 years</b>	504	0.035 (0.022)		0.009 (0.023)		0.009 (0.021)		-0.024 (0.021)		-0.073 (0.020)	***	-0.083 (0.018)	***	-0.071 (0.019) ***
<b>&gt;3 years</b>	152	-0.026 (0.039)		-0.106 (0.041)	**	-0.026 (0.036)		-0.066 (0.037)		-0.126 (0.034)	***	-0.181 (0.031)	***	-0.111 (0.032) ***

Each value is the adjusted cognitive z-score difference between two groups.

AC, anticholinergic drug; DSST, Digit Symbol Substitution Test; TMT, A and B, Trail Making Test; SE, standard error

<sup>1</sup>Lifestyle variables: living with a partner, smoking status, alcohol consumption, physical activity, body mass index

<sup>2</sup>Health status variables: self-rated health status, depressive symptoms, diabetes, respiratory diseases, cardiovascular diseases, osteoarticular disease, hypercholesterolemia, and cancer.

P value: \*, 0.01 to 0.05; \*\*, 0.001 to 0.01; \*\*\*, < 0.001

**e-Table 3: Sensitivity analysis of associations linking cumulative anticholinergic drug exposure over the 3 years before cognitive testing and z-scores on cognitive tests, adjusted on lifestyle<sup>a</sup> and health status<sup>b</sup> variables, excluding participants with antipsychotics deliveries (n=33 949)**

Cumulative AC exposure	<i>Episodic memory</i>		<i>Verbal fluency</i>		<i>Executive functions</i>			
	<i>Immediate free recall</i>	<i>Delayed free recall</i>	<i>Semantic fluency</i>	<i>Phonemic fluency</i>	<i>DSST</i>	<i>TMT-A</i>	<i>TMT-B</i>	
	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	
		<i>Adjusted on lifestyle<sup>a</sup> and health status<sup>b</sup> variables</i>						
<i>None</i>	18 095	Ref	Ref	Ref	Ref	Ref	Ref	
<3 months	10 390	-0.014 (0.012)	-0.016 (0.012)	-0.021 (0.012)	0.000 (0.012)	-0.002 (0.012)	-0.013 (0.012)	-0.015 (0.012)
3-12 months	3322	-0.057 (0.019) **	-0.047 (0.019) *	-0.037 (0.019)	-0.005 (0.019)	-0.028 (0.019)	-0.009 (0.019)	-0.026 (0.019)
1-3 years	1682	0.019 (0.026)	0.003 (0.026)	-0.023 (0.026)	0.017 (0.026)	-0.020 (0.026)	-0.037 (0.026)	-0.006 (0.026)
>3 years	460	-0.049 (0.048)	-0.050 (0.048)	0.013 (0.048)	-0.035 (0.048)	-0.104 (0.048) *	-0.097 (0.048) *	-0.089 (0.048)

Each value is the adjusted cognitive z-score difference between two groups.

AC, anticholinergic drug; DSST, Digit Symbol Substitution Test; TMT, A and B, Trail Making Test

<sup>a</sup>Lifestyle variables: living with a partner, smoking status, alcohol consumption, physical activity, body mass index

<sup>b</sup>Health status variables: self-rated health status, depressive symptoms, diabetes, respiratory diseases, cardiovascular diseases, osteoarticular disease, hypercholesterolemia, and cancer.

P values: 0.05 to 0.10; \*, 0.01 to 0.05; \*\*, 0.001 to 0.01; \*\*\*, < 0.001

**e-Table 4: Associations linking cumulative exposure to anticholinergic drugs over a 3-year period and z-scores on cognitive function tests according to anticholinergic class<sup>1</sup>, adjusted on lifestyle<sup>2</sup> and health status<sup>3</sup> variables (n=30315), “analysis restricted on ACB-1 drugs”.**

Cumulative AC exposure			Episodic memory		Verbal fluency		Executive functions			
			Immediate free recall	Delayed free recall	Semantic fluency	Phonemic fluency	DSST	TMT-A	TMT-B	
			Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	Estimate (SE)	
Antihistamines	None	24230	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	5670	<b>0.020</b> (0.007) **	<b>0.004</b> (0.007)	<b>-0.010</b> (0.007)	<b>0.012</b> (0.007)	<b>0.014</b> (0.007) *	<b>0.024</b> (0.007) ***	<b>0.031</b> (0.007) ***	
	≥ 1 year	415	<b>0.048</b> (0.022) *	<b>0.050</b> (0.022) *	<b>-0.038</b> (0.022)	<b>0.022</b> (0.022)	<b>0.056</b> (0.022) *	<b>0.036</b> (0.022)	<b>0.081</b> (0.022) ***	
Opioids	None	26486	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	3793	<b>-0.038</b> (0.008) ***	<b>-0.041</b> (0.008) ***	<b>-0.002</b> (0.008)	<b>-0.010</b> (0.008)	<b>-0.003</b> (0.008)	<b>-0.002</b> (0.008)	<b>-0.014</b> (0.008)	
	≥ 1 year	36	<b>-0.208</b> (0.074) **	<b>-0.018</b> (0.074)	<b>0.076</b> (0.075)	<b>0.162</b> (0.075) *	<b>-0.016</b> (0.074)	<b>0.134</b> (0.074)	<b>-0.003</b> (0.075)	
Alimentary tract and metabolism drugs	None	26670	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	3594	<b>0.017</b> (0.008) *	<b>0.012</b> (0.008)	<b>-0.003</b> (0.008)	<b>-0.005</b> (0.008)	<b>0.009</b> (0.008)	<b>-0.017</b> (0.008) *	<b>-0.027</b> (0.008) ***	
	≥ 1 year	51	<b>0.134</b> (0.063) *	<b>-0.065</b> (0.062)	<b>-0.115</b> (0.063)	<b>-0.133</b> (0.063) *	<b>-0.146</b> (0.062) *	<b>-0.197</b> (0.063) **	<b>-0.276</b> (0.063) ***	
Anxiolytic drugs	None	28596	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	1643	<b>-0.048</b> (0.012) ***	<b>-0.045</b> (0.012) ***	<b>-0.035</b> (0.012) **	<b>0.001</b> (0.012)	<b>-0.004</b> (0.011)	<b>-0.017</b> (0.012)	<b>-0.012</b> (0.012)	
	≥ 1 year	76	<b>-0.095</b> (0.052)	<b>-0.157</b> (0.051) **	<b>0.021</b> (0.052)	<b>0.019</b> (0.052)	<b>-0.103</b> (0.051) *	<b>-0.098</b> (0.052)	<b>-0.119</b> (0.052) *	
Antidepressant drugs	None	29881	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	265	<b>-0.001</b> (0.028)	<b>0.022</b> (0.028)	<b>0.052</b> (0.028)	<b>0.107</b> (0.028) ***	<b>0.069</b> (0.028) *	<b>0.090</b> (0.028) **	<b>0.058</b> (0.028) *	

	≥ 1 year	169	<b>0.068</b> (0.035)	-0.047 (0.035)	<b>0.103</b> (0.035) **	<b>0.070</b> (0.035) *	-0.087 (0.035) *	-0.141 (0.035) ***	-0.114 (0.035) **
Cardiovascular system drugs	None	29579	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	410	-0.092 (0.022) ***	0.001 (0.022)	-0.020 (0.022)	0.032 (0.022)	-0.046 (0.022) *	-0.090 (0.022) ***	-0.075 (0.022) ***
	≥ 1 year	326	<b>0.076</b> (0.025) **	<b>0.139</b> (0.025) ***	<b>0.042</b> (0.025)	<b>0.001</b> (0.025)	-0.097 (0.025) ***	-0.116 (0.025) ***	-0.043 (0.025)
Antipsychotics	None	30247	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	50	-0.249 (0.063) ***	-0.245 (0.063) ***	-0.151 (0.064) *	-0.262 (0.064) ***	-0.286 (0.063) ***	-0.018 (0.063)	-0.356 (0.064) ***
	≥ 1 year	18	-0.210 (0.105) *	-0.496 (0.105) ***	-0.700 (0.106) ***	-0.378 (0.106) ***	-0.968 (0.105) ***	-0.761 (0.105) ***	-0.627 (0.106) ***
Other AC drugs	None	28235	Ref	Ref	Ref	Ref	Ref	Ref	Ref
	<1 year	1963	-0.022 (0.011) *	-0.040 (0.011) ***	0.008 (0.011)	-0.005 (0.011)	-0.025 (0.011) *	-0.056 (0.011) ***	-0.017 (0.011)
	≥ 1 year	117	<b>0.040</b> (0.041)	<b>0.017</b> (0.041)	-0.055 (0.042)	<b>0.101</b> (0.042) *	-0.072 (0.041)	-0.078 (0.041)	-0.045 (0.042)

Values are given as the adjusted difference between two groups in terms of cognitive z-score.

AC, anticholinergic drug; DSST, Digit Symbol Substitution Test; TMT, A and B, Trail Making Test; ATC, Anatomical Therapeutic Chemical classification system; ACB, Anticholinergic Cognitive Burden scale.

<sup>1</sup>Drug classes of anticholinergic agents were determined based on the ATC classification level.

<sup>2</sup>Lifestyle variables: living with a partner, smoking status, alcohol consumption, physical activity, body mass index.

<sup>3</sup>Health status variables: self-rated health status, depressive symptoms, diabetes, respiratory diseases, cardiovascular diseases, osteoarticular disease, hypercholesterolemia, and cancer.

P value: \*, 0.01 to 0.05; \*\*, 0.001 to 0.01; \*\*\*, < 0.001